Premium
Short‐term versus long‐term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer
Author(s) -
Klijn J. G. M.,
De Voogt H. J.,
Studer U. E.,
Schröder F. H.,
Sylvester R.,
De Pauw M.
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19931215)72:12+<3858::aid-cncr2820721719>3.0.co;2-6
Subject(s) - cyproterone acetate , buserelin , medicine , cyproterone , prostate cancer , antiandrogen , urology , leuprorelin , luteinizing hormone , cancer , agonist , hormone , endocrinology , androgen , receptor
In an open, multicenter, three‐armed, randomized study, we compared the effects of short‐term (2 weeks) and continuous addition of the antiandrogen cyproterone acetate to the luteinizing hormone‐releasing hormone agonist buserelin to those of orchidectomy in patients with advanced prostate cancer. No significant differences among the three treatment arms with respect to response rate, subjective response, time‐to‐progression, overall survival, and cancer deaths were observed. It was concluded that the short‐term or continuous addition of cyproterone acetate to buserelin administered intranasally did not improve treatment results compared to orchidectomy only.